multiple sclerosis

[Cell Research] The authors identified K2P18.1 as a central translator of the T cell receptor signal into the thymus-derived Treg (tTreg) selection process.

[Lancet Neurology] Bone marrow-derived MSC treatment was safe and well tolerated but did not show an effect on gadolinium-enhancing lesions, an MRI surrogate marker of acute inflammation, in patients with active forms of multiple sclerosis, at week 24.

[Cell Death & Disease] Researchers found that YAP was upregulated and activated in astrocytes of spinal cords of encephalomyelitis mice through suppression of the Hippo pathway.

[TG Therapeutics, Inc.] TG Therapeutics, Inc. announced the submission of a Biologics License Application to the FDA requesting approval of ublituximab, the company’s investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis.

[Nature Reviews Gastroenterology & Hepatology] The authors consolidate knowledge on diet–microbiome interactions in local inflammation, gut microbiota imbalance and host immune dysregulation.

[Nature Medicine] The authors investigated induction of antigen-specific antibody, B cell and T cell responses longitudinally in patients with multiple sclerosis on anti-CD20 antibody monotherapy compared with healthy controls after BNT162b2 or mRNA-1273 mRNA vaccination.